S
688217
vs
S
Shanghai Composite
Over the past 12 months, Shanghai Rightongene Biotechnology Co Ltd has outperformed Shanghai Composite, delivering a return of +37% compared to the Shanghai Composite's +23% growth.
Stocks Performance
688217 vs Shanghai Composite
Performance Gap
688217 vs Shanghai Composite
Performance By Year
688217 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shanghai Rightongene Biotechnology Co Ltd
Glance View
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. The company is headquartered in Shanghai, Shanghai and currently employs 503 full-time employees. The company went IPO on 2021-05-17. The firm's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The firm mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The firm also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The firm mainly conducts its businesses within domestic market.
